Lack of effect of different pain-related manipulations on opioid self-administration, reinstatement of opioid seeking, and opioid choice in rats.

Szczegóły
Abstrakt

Tytuł:: Lack of effect of different pain-related manipulations on opioid self-administration, reinstatement of opioid seeking, and opioid choice in rats.
Autorzy:: Reiner DJ; Behavioral Neuroscience Branch, IRP/NIDA/NIH, Baltimore, MD, USA. .; NIGMS, Bethesda, MD, USA. .
Townsend EA; Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Orihuel J; Behavioral Neuroscience Branch, IRP/NIDA/NIH, Baltimore, MD, USA.
Applebey SV; Behavioral Neuroscience Branch, IRP/NIDA/NIH, Baltimore, MD, USA.
Claypool SM; Behavioral Neuroscience Branch, IRP/NIDA/NIH, Baltimore, MD, USA.
Banks ML; Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Shaham Y; Behavioral Neuroscience Branch, IRP/NIDA/NIH, Baltimore, MD, USA.
Negus SS; Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA, USA. .
Źródło:: Psychopharmacology [Psychopharmacology (Berl)] 2021 Jul; Vol. 238 (7), pp. 1885-1897. Date of Electronic Publication: 2021 Mar 25.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Berlin, New York, Springer-Verlag.
MeSH Terms:: Reinforcement, Psychology*
Analgesics, Opioid/*administration & dosage
Choice Behavior/*drug effects
Drug-Seeking Behavior/*drug effects
Pain/*psychology
Pain Measurement/*psychology
Animals ; Choice Behavior/physiology ; Conditioning, Operant/drug effects ; Conditioning, Operant/physiology ; Drug-Seeking Behavior/physiology ; Extinction, Psychological/drug effects ; Extinction, Psychological/physiology ; Female ; Fentanyl/pharmacology ; Male ; Opioid-Related Disorders/psychology ; Pain/drug therapy ; Pain Measurement/methods ; Rats ; Self Administration/methods
References:: Subst Abus. 2012;33(4):361-5. (PMID: 22989279)
Pain. 2001 Mar;91(1-2):33-45. (PMID: 11240076)
Pain Physician. 2017 Feb;20(2S):S93-S109. (PMID: 28226333)
J Neurosci. 2015 Sep 02;35(35):12217-31. (PMID: 26338332)
Pharmacol Biochem Behav. 1988 Oct;31(2):445-51. (PMID: 3244721)
Drug Alcohol Depend. 2020 Apr 1;209:107902. (PMID: 32088587)
PLoS One. 2016 Feb 25;11(2):e0150164. (PMID: 26915030)
Clin J Pain. 2009 Mar-Apr;25(3):193-8. (PMID: 19333168)
J Pain. 2002 Aug;3(4):309-19. (PMID: 14622755)
Drug Alcohol Depend. 2019 Nov 1;204:107501. (PMID: 31479865)
Neuropsychopharmacology. 2016 Jan;41(1):335-56. (PMID: 25976297)
JAMA. 2003 May 14;289(18):2370-8. (PMID: 12746360)
Mol Pain. 2014 Sep 23;10:62. (PMID: 25245060)
Psychopharmacology (Berl). 2003 Jul;168(1-2):3-20. (PMID: 12402102)
Psychopharmacology (Berl). 2020 Jul;237(7):2201-2212. (PMID: 32382785)
Neuropsychopharmacology. 1996 Jun;14(6):375-424. (PMID: 8726752)
J Pharmacol Exp Ther. 2015 Feb;352(2):208-17. (PMID: 25406170)
J Pain. 2005 Dec;6(12):798-808. (PMID: 16326368)
Neuropsychopharmacology. 2019 Nov;44(12):2022-2029. (PMID: 30818323)
J Med Toxicol. 2012 Dec;8(4):393-9. (PMID: 23073725)
Neuropharmacology. 2021 Mar 15;186:108476. (PMID: 33524407)
Drug Alcohol Depend. 1980 Sep;6(3):163-73. (PMID: 6107237)
Life Sci. 1989;45(23):2217-24. (PMID: 2601574)
J Subst Abuse Treat. 2017 Jun;77:26-30. (PMID: 28476267)
Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3233-43. (PMID: 18640922)
PLoS One. 2013 Nov 15;8(11):e79239. (PMID: 24260176)
Neurology. 2007 Apr 10;68(15):1178-82. (PMID: 17420400)
Neurosci Lett. 2016 Oct 6;632:44-9. (PMID: 27544012)
Behav Brain Res. 2006 Jun 30;170(2):308-15. (PMID: 16675039)
Front Pharmacol. 2021 Jan 29;11:615782. (PMID: 33584295)
Nat Rev Neurosci. 2020 Nov;21(11):625-643. (PMID: 33024318)
Pharmacol Biochem Behav. 2011 Mar;98(1):35-42. (PMID: 21147151)
Nat Methods. 2010 Jun;7(6):447-9. (PMID: 20453868)
Pain Res Manag. 2011 May-Jun;16(3):169-77. (PMID: 21766066)
ACS Chem Neurosci. 2020 May 6;11(9):1300-1310. (PMID: 32271538)
Brain Res Brain Res Rev. 2000 Aug;33(1):13-33. (PMID: 10967352)
Neuropharmacology. 2019 Dec 1;160:107689. (PMID: 31271771)
Pain. 1996 Sep;67(1):179-188. (PMID: 8895246)
Prog Brain Res. 2010;186:141-57. (PMID: 21094890)
Eur J Pain. 2012 Apr;16(4):485-95. (PMID: 22396078)
Adv Pharmacol Sci. 2012;2012:281768. (PMID: 23243420)
Pain Physician. 2017 Feb;20(2S):S111-S133. (PMID: 28226334)
J Subst Abuse Treat. 2014 Aug;47(2):140-5. (PMID: 24814051)
Psychopharmacology (Berl). 2018 May;235(5):1609-1618. (PMID: 29572653)
Psychopharmacology (Berl). 1980;70(2):213-7. (PMID: 6776582)
Nature. 1983 Mar 17-23;302(5905):251-3. (PMID: 6188055)
J Pharmacol Exp Ther. 2012 Nov;343(2):389-400. (PMID: 22892341)
Behav Neurosci. 2002 Feb;116(1):169-73. (PMID: 11895178)
Neuropsychopharmacology. 2019 Sep;44(10):1681-1689. (PMID: 31043682)
Lab Anim (NY). 2013 Aug;42(8):292-300. (PMID: 23877610)
Neuropsychopharmacology. 2015 Jan;40(2):421-8. (PMID: 25060491)
Neuropharmacology. 2019 May 15;150:200-209. (PMID: 30660628)
Behav Pharmacol. 2021 Apr 1;32(2&3):142-152. (PMID: 33079736)
Trends Pharmacol Sci. 2017 Feb;38(2):181-194. (PMID: 27916279)
J Subst Abuse Treat. 2010 Jun;38 Suppl 1:S80-6. (PMID: 20307799)
Life Sci. 1982 Jul 5;31(1):67-75. (PMID: 7109855)
Pharmacol Rev. 2019 Apr;71(2):225-266. (PMID: 30898855)
Sci Signal. 2016 Nov 29;9(456):ra117. (PMID: 27899527)
Prog Neurobiol. 2011 Mar;93(3):385-404. (PMID: 21216272)
Pain. 2008 Sep 30;139(1):127-135. (PMID: 18455314)
Pain. 2009 Jul;144(1-2):170-7. (PMID: 19435650)
Psychopharmacology (Berl). 2020 Nov;237(11):3369-3381. (PMID: 32990768)
Anesthesiology. 2007 Feb;106(2):312-22. (PMID: 17264726)
Pain. 1992 Apr;49(1):129-135. (PMID: 1594274)
J Pharmacol Exp Ther. 1977 Sep;202(3):660-9. (PMID: 19619)
J Pain. 2012 Feb;13(2):146-54. (PMID: 22245713)
Exp Clin Psychopharmacol. 2008 Oct;16(5):357-66. (PMID: 18837632)
Pain. 2006 Sep;124(1-2):34-49. (PMID: 16650579)
MMWR Morb Mortal Wkly Rep. 2018 Sep 14;67(36):1001-1006. (PMID: 30212442)
Mol Pain. 2011 Jul 29;7:55. (PMID: 21801409)
Trends Pharmacol Sci. 2018 Nov;39(11):911-916. (PMID: 30343726)
Exp Clin Psychopharmacol. 2015 Oct;23(5):405-14. (PMID: 26375515)
Anesthesiology. 2004 Jul;101(1):191-203. (PMID: 15220791)
Grant Information:: 1FI2GM128603 United States GM NIGMS NIH HHS; P30 DA033934 United States DA NIDA NIH HHS; P30DA0333034 United States DA NIDA NIH HHS; F32DA047026 United States DA NIDA NIH HHS; Funds of Intramural Research Program United States DA NIDA NIH HHS
Contributed Indexing:: Keywords: Extinction; Opioid choice; Opioid self-administration; Pain; Reinstatement; Relapse
Substance Nomenclature:: 0 (Analgesics, Opioid)
UF599785JZ (Fentanyl)
Entry Date(s):: Date Created: 20210325 Date Completed: 20210705 Latest Revision: 20230328
Update Code:: 20240105
PubMed Central ID:: PMC10041878
DOI:: 10.1007/s00213-021-05816-9
PMID:: 33765177
: Czasopismo naukowe

Pełny tekst

Rationale and Objective: Pain-related factors increase the risk for opioid addiction, and pain may function as a negative reinforcer to increase opioid taking and seeking. However, experimental pain-related manipulations generally do not increase opioid self-administration in rodents. This discrepancy may reflect insufficient learning of pain-relief contingencies or confounding effects of pain-related behavioral impairments. Here, we determined if pairing noxious stimuli with opioid self-administration would promote pain-related reinstatement of opioid seeking or increase opioid choice over food.
Methods: In Experiment 1, rats self-administered fentanyl in the presence or absence of repeated intraplantar capsaicin injections in distinct contexts to model context-specific exposure to cutaneous nociception. After capsaicin-free extinction in both contexts, we tested if capsaicin would reinstate fentanyl seeking. In Experiment 2, rats self-administered heroin after intraperitoneal (i.p.) lactic acid injections to model acute visceral inflammatory pain. After lactic acid-free extinction, we tested if lactic acid would reinstate heroin seeking. In Experiment 3, we tested if repeated i.p. lactic acid or intraplantar Complete Freund's Adjuvant (CFA; to model sustained inflammatory pain) would increase fentanyl choice over food.
Results: In Experiments 1-2, neither capsaicin nor lactic acid reinstated opioid seeking after extinction, and lactic acid did not increase heroin-induced reinstatement. In Experiment 3, lactic acid and CFA decreased reinforcement rate without affecting fentanyl choice.
Conclusions: Results extend the range of conditions across which pain-related manipulations fail to increase opioid seeking in rats and suggest that enhanced opioid-addiction risk in humans with chronic pain involves factors other than enhanced opioid reinforcement and relapse.

Informacja